Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LONGITUDINAL REAL-WORLD STUDY OF FIRST-LINE (1L) LORLATINIB IN THE UNITED STATES: PERFORMANCE STATUS AND TREATMENT PATTERNS

NCT07567352 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT07567352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07567352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LONGITUDINAL REAL-WORLD STUDY OF FIRST-LINE (1L) LORLATINIB IN THE UNITED STATES: PERFORMANCE STATUS AND TREATMENT PATTERNS
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
May 1, 2026
Completion date
March 1, 2027
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive advanced nsclc, alk-positive non-small-cell lung cancer, alk-positive nsclc, non-small-cell lung